• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Ekso Bionics Holdings Inc.

    5/29/25 4:29:10 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email
    S-8 1 ekso20250527_s8.htm FORM S-8 ekso20250527_s8.htm

    As filed with the Securities and Exchange Commission on May 29, 2025

     

    Registration No. 333-

     



    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     


     

    EKSO BIONICS HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     


    Nevada

     

    99-0367049

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     


    Ekso Bionics Holdings, Inc.

    101 Glacier Point, Suite A

    San Rafael, California, 94901

    (Address of principal executive offices) (Zip code)

     


    Amended and Restated 2014 Equity Incentive Plan

    (Full title of the plan)

     


     

    Scott G. Davis, Chief Executive Officer

    101 Glacier Point, Suite A

    San Rafael, California, 94901

    (510) 984-1761

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     
         
     

    Mark B. Baudler

    Austin D. March

    Wilson Sonsini Goodrich &

    Rosati, Professional Corporation

    650 Page Mill Road

    Palo Alto, CA 94304

    (650) 493-9300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

       

    Accelerated filer  ☐

    Non-accelerated filer  ☒

       

    Smaller reporting company  ☒

         

    Emerging growth company  ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E

     

    This Registration Statement on Form S-8 (the “Registration Statement”) registers additional shares of common stock of Ekso Bionics Holdings, Inc. (the “Registrant”) to be issued pursuant to the Registrant's Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”). Pursuant to General Instruction E of Form S-8 under the Securities Act, the Registrant incorporates by reference into this Registration Statement the contents of (a) the registration statement on Form S-8 (File No. 333-198357), filed with the Securities and Exchange Commission (the “SEC”) on August 26, 2014, relating to the registration of 137,238 shares of Registrant’s common stock authorized for issuance under the 2014 Plan (taking into account a 1-for-7 reverse stock split on May 4, 2016 and a 1-for-15 reverse stock split on March 24, 2020), (b) the registration statement on Form S-8 (File No. 333-207131), filed with the SEC on September 25, 2015, relating to the registration of 110,380 shares of Registrant’s common stock authorized for issuance under the 2014 Plan (taking into account a 1-for-7 reverse stock split on May 4, 2016 and a 1-for-15 reverse stock split on March 24, 2020), (c) the registration statement on Form S-8 (File No. 333-220808), filed with the SEC on October 4, 2017, relating to the registration of 66,666 shares of Registrant’s common stock authorized for issuance under the 2014 Plan (taking into account a 1-for-15 reverse stock split on March 24, 2020), (d) the registration statement on Form S-8 (File No. 333-226037), filed with the SEC on July 2, 2018, relating to the registration of 293,333 shares of Registrant’s common stock authorized for issuance under the 2014 Plan (taking into account a 1-for-15 reverse stock split on March 24, 2020), (e) the registration statement on Form S-8 (File No. 333-232512), filed with the SEC on July 2, 2019, relating to the registration of 233,333 shares of Registrant’s common stock authorized for issuance under the 2014 Plan (taking into account a 1-for-15 reverse stock split on March 24, 2020), (f) the registration statement on Form S-8 (File No. 333-237527), filed with the SEC on April 1, 2020, relating to the registration of 333,334 shares of Registrant’s common stock authorized under the 2014 Plan, (g) the registration on Form S-8 (File No. 333-253526), filed with the SEC on February 25, 2021, relating to the registration of 800,000 shares of Registrant’s common stock authorized under the 2014 Plan, (h) the registration on Form S-8 (File No. 333-266218), filed with the SEC on July 19, 2022, relating to the registration of 550,000 shares of Registrant’s common stock authorized under the 2014 Plan, (i) the registration on Form S-8 (File No. 333-272610), filed with the SEC on June 13, 2023, relating to the registration of 1,200,000 shares of Registrant’s common stock authorized under the 2014 Plan, and (j) the registration on Form S-8 (333-281086) filed with the SEC on July 29, 2024, relating to the registration of 1,000,000 shares of Registrant’s common stock authorized under the 2014 Plan, in each case, in their entirety and including exhibits thereto. This Registration Statement provides for the registration of the 2,300,000 shares of the Registrant’s common stock to be issued under the 2014 Plan. These 2,300,000 shares represent an increase in the number of shares of common stock reserved for issuance under the 2014 Plan, which increase was approved by the stockholders on May 16, 2025. As a result of the foregoing, the total number of shares of the Registrant’s common stock registered for offer and sale under the 2014 Plan is now 7,024,286 (taking into account a 1-for-7 reverse stock split on May 4, 2016 and a 1-for-15 reverse stock split on March 24, 2020). On May 16, 2025, the stockholders of the Registrant approved a 1-for-15 reverse stock split. On June 2, 2025, upon the effectiveness of such reverse stock split, the total number of shares of the Registrant’s common stock registered for offer and sale under the 2014 Plan will be reduced to 468,285.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.         Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference into this Registration Statement the following documents that the Registrant has previously filed with the SEC:

     

     

    (1)

    The Registrant’s Annual Report on Form 10-K  for the fiscal year ended December 31, 2024 filed with the SEC on March 3, 2025, including the sections of the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 10, 2025 (the “Annual Report”);

     

     

    (2)

    All other reports filed by the Registrant with the Commission pursuant to Sections 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in clause (1) above (other than the portions of these documents not deemed to be filed); and

     

     

     

     

     

    (3)

    The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-37854) filed with the SEC on August 8, 2016, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.9 of the Annual Report.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

     

     

    Exhibit

    Number

     

    Description

    Form

    File Number

    Exhibit

    Filing Date

    4.1

     

    Restated Articles of Incorporation of the Registrant

    8-K

    001-37854

    3.1

    April 26, 2023

                 

    4.2

     

    Amended and Restated By-Laws of the Registrant

    8-K

    001-37854

    3.2

    April 26, 2023

                 

    4.3

     

    Form of specimen certificate

    S-3

    333-205168

    4.4

    June 23, 2015

                 

    4.4*

     

    Amended and Restated 2014 Equity Incentive Plan

           
                 

    4.5

     

    Form of Director Option Agreement under Amended and Restated 2014 Equity Incentive Plan

    8-K

    001-37854

    10.13

    January 23, 2014

                 

    4.6

     

    Form of Employee Option Agreement under Amended and Restated 2014 Equity Incentive Plan

    8-K

    001-37854

    10.14

    January 23, 2014

                 

    4.7

     

    Form of Restricted Stock Unit Award under Amended and Restated 2014 Equity Incentive Plan

    S-1

    333-281081

    10.7

    July 29, 2024

                 

    5.1*

     

    Opinion of Snell and Wilmer L.L.P

           
                 

    23.1*

     

    Consent of WithumSmith+Brown, PC

           
                 

    23.2*

     

    Consent of Snell and Wilmer L.L.P. (included in Exhibit 5.1)

           
                 

    24.1*

     

    Power of Attorney (included in signature pages hereto).

           
                 

    107*

     

    Filing Fee Table

           

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Rafael, State of California, on May 29, 2025.

     

     

    EKSO BIONICS HOLDINGS, INC.

    By:

    /s/ Scott G. Davis

     

    Scott G. Davis

     

    Chief Executive Officer

     

    SIGNATURES AND POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Scott G. Davis and Jerome Wong, or either one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments or supplements (including post-effective amendments filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended) to this registration statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent or either one of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully as to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or any of them, or his substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

    Signatures

     

    Title

     

    Date

             

    /s/ Scott G. Davis

     

    Chief Executive Officer and Director

    (principal executive officer)

     

    May 29, 2025

    Scott G. Davis

           
             

    /s/ Jerome Wong

     

    Chief Financial Officer and Corporate Secretary

      May 29, 2025

    Jerome Wong

      (principal financial and accounting officer)    
             

    /s/ Mary Ann Cloyd

     

    Director

      May 29, 2025

    Mary Ann Cloyd

           
             

    /s/ Corinna Lathan

     

    Director

      May 29, 2025

    Corinna Lathan, Ph.D.

           
             

    /s/ Charles Li

     

    Director

      May 29, 2025

    Charles Li, Ph.D.

           
             

    /s/ Deborah Lafer Scher

     

    Director

      May 29, 2025

    Deborah Lafer Scher

           

     

     
    Get the next $EKSO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ekso Bionics Announces New Effective Date of Reverse Stock Split

      SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the "Company") (NASDAQ:EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol "EKSO". The Company's common stock will trade under a new CUSIP number 282644 400 upon the effec

      5/21/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Announces Reverse Stock Split

      SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the "Company") (NASDAQ:EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol "EKSO". The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. Upon the effectiveness of the reverse stock split, the number of shar

      5/19/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

      Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie

      6/17/24 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

      Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti

      12/5/22 8:37:01 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cloyd Mary Ann was granted 236,202 shares, increasing direct ownership by 107% to 456,707 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      5/19/25 7:07:33 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Director Lathan Corinna was granted 236,202 shares, increasing direct ownership by 104% to 462,409 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      5/19/25 7:07:01 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Director Li Kecheng was granted 236,202 shares, increasing direct ownership by 105% to 460,940 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      5/19/25 7:06:28 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lathan Corinna bought $15,477 worth of shares (13,733 units at $1.13), increasing direct ownership by 10% to 147,990 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/14/24 6:41:52 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Financials

    Live finance-specific insights

    See more
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

      SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry "We are pleased to close out 2024 with recor

      3/3/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      11/14/24 3:29:01 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

      SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/11/22 6:17:59 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/12/21 10:16:25 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    SEC Filings

    See more
    • SEC Form S-8 filed by Ekso Bionics Holdings Inc.

      S-8 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/29/25 4:29:10 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/21/25 4:43:10 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form 10-Q filed by Ekso Bionics Holdings Inc.

      10-Q - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:08:10 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials